GenVec Inc. said Wednesday it plans to run a clinical study on an experimental malaria vaccine.
GenVec has been working for four years with the Navy Medical Research Center to develop a vaccine to fight the mosquito-borne disease that kills an estimated 1 million people in Africa each year.
In a first phase, the study will evaluate the safety of a recombinant adenoviros vaccine that uses GenVec gene delivery and cell culture manufacturing technologies. The study's second phase will evaluate the protective effects of the vaccine following exposure to malaria.
The Gaithersburg, Md., company plans to conduct the study with the Naval Medical Research Center under sponsorship by the U.S. Army Medical Materiel Development Activity. The U.S. Agency for International Development is providing unspecified financial support.
In electronic premarket trading, GenVec shares added 9 cents, or 3.6 percent, to $2.59, after closing Tuesday at $2.50 on the Nasdaq Stock Market.